| Symlin (pramlintide) / AstraZeneca |
NCT00044707: Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide |
|
|
| Completed | 2 | 24 | US | Pramlintide acetate | AstraZeneca | Diabetes Mellitus, Non-Insulin-Dependent | 09/02 | 09/02 | | |
NCT00042471: Evaluation of the Bioavailability of Pramlintide |
|
|
| Completed | 2 | 75 | US | Pramlintide acetate, Symlin (pramlintide acetate) | AstraZeneca | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 12/02 | 12/02 | | |
NCT00042601: Evaluation of the Effect of Pramlintide on Satiety and Food Intake |
|
|
| Completed | 2 | 51 | RoW | Pramlintide acetate, Placebo | AstraZeneca | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/03 | 10/03 | | |
NCT00313183: A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus |
|
|
| Completed | 2 | 12 | US | pramlintide acetate, Symlin | AstraZeneca | Type 1 Diabetes Mellitus | 08/07 | 08/07 | | |
NCT01165944: Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus |
|
|
| Withdrawn | 1/2 | 0 | US | Pramlintide | University of Colorado, Denver, Amylin Pharmaceuticals, LLC. | Diabetes Mellitus | 08/11 | 08/11 | | |
